A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03872947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.
Study identification
- NCT ID
- NCT03872947
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Interventions
- TRK-950 Biological
- Irinotecan Drug
- Leucovorin Drug
- 5-FU Drug
- Gemcitabine Drug
- Cisplatin Drug
- Carboplatin Drug
- Ramucirumab Drug
- Paclitaxel Drug
- Nivolumab Drug
- Pembrolizumab Drug
- Imiquimod Cream Drug
- Bevacizumab Drug
- PLD Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2019 (Actual)
- Primary completion
- Jul 16, 2026 (Actual)
- Completion
- Jul 16, 2026 (Actual)
- Last update posted
- Oct 8, 2026
2019 – 2026
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | — |
| AOA-HOPE | Tucson | Arizona | 85711 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| HOAG Memorial Hospital Presbyterian | Newport | California | 92663 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Perlmutter Cancer Center at NYU Langone | New York | New York | 10016 | — |
| Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center) | Eugene | Oregon | 97401 | — |
| Northwest Cancer Specialists | Portland | Oregon | 97227 | — |
| Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology - Downtown Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| Virginia Cancer Specialists, PC | Leesburg | Virginia | 20176 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03872947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03872947 live on ClinicalTrials.gov.